Inherited Thrombophilia, Pregnancy, and Oral Contraceptive Use: Clinical Implications

 

 Buy Article Permissions and Reprints

ABSTRACT

Inherited thrombophilia has been reported to be associated with an increased risk for complications of pregnancy, including venous thromboembolism (VTE) as well as preeclampsia (PEC), fetal loss (FL), fetal growth retardation (FGR), and abruptio placentae (AP), the latter probably due to inadequate placental perfusion. The estimate of risk largely depends on the kind of thrombophilia and on the criteria applied for the selection of the patients, producing in some cases contradictory results. Convincing evidence is available that deficiency of antithrombin III (AT), protein C (PC), and protein S (PS) is a risk factor for VTE and late FL. Factor V_Leiden is associated with an increased risk for VTE, unexplained recurrent FL, late FL, and perhaps PEC; prothrombin G20210A is a weak risk factor for VTE. So far, the data available for FGR and AP are scarce. However, the absolute risk for VTE during pregnancy and puerperium is between 1 and 3%, in comparison with the baseline risk of 0.08%. Antithrombotic prophylaxis with subcutaneous heparin is warranted during puerperium in all women with thrombophilia and throughout all pregnancy in women at higher risk (AT deficiency, homozygosity for factor VLeiden, and perhaps PC and PS deficiencies); treatment with subcutaneous heparin for prevention of FL among women with thombophilia is under investigation. Presence of inherited thrombophilia increases the risk for VTE due to oral contraceptives up to an absolute risk of 3 per 1000 person-years, in comparison with the baseline risk of 3 to 6 per 10,000 person-years; the risk is further increased by first usage, the use of preparations containing third-generation progestins, and thrombophilia due to AT, PC, and PS deficiency as well as homozygous factor V_Leiden and combined defects.

REFERENCES

• 1 Lane D A, Mannucci P M, Bauer K A. et al . Inherited thrombophilia: Part 1.  Thomb Haemost . 1996;  76 651-662
  PubMedGoogle Scholar
• 2 Jordan F LJ, Nandorff A. The familial tendency in thromboembolic disease.  Acta Med Scand . 1956;  156 267-275
  CrossrefPubMedGoogle Scholar
• 3 Egeberg O. Inherited antithrombin deficiency causing thrombophilia.  Thromb Diath Haemorrh . 1965;  13 516-530
  PubMedGoogle Scholar
• 4 Griffin J, Evatt B, Zimmerman T, Kleiss A, Wideman C. Deficiency of protein C in congenital thrombotic disease.  J Clin Invest . 1981;  68 1370-1373
  CrossrefPubMedGoogle Scholar
• 5 Comp P, Esmon C. Recurrent venous thromboembolism in patients with a partial deficiency of protein S.  N Engl J Med . 1984;  311 1525-1528
  CrossrefPubMedGoogle Scholar
• 6 Schwarz H P, Fischer M, Hopmeier P, Batard M, Griffin J. Plasma protein S deficiency in familial thrombotic disease.  Blood . 1984;  64 1297-1300
  PubMedGoogle Scholar
• 7 De Stefano V, Finazzi G, Mannucci P M. Inherited thrombophilia: pathogenesis, clinical syndromes, and management.  Blood . 1996;  87 3531-3544
  PubMedGoogle Scholar
• 8 Dahlback B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.  Proc Natl Acad Sci U S A . 1993;  90 1004-1008
  PubMedGoogle Scholar
• 9 Koster T, Rosendaal F R, de Ronde H. et al . Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.  Lancet . 1993;  342 1503-1506
  CrossrefPubMedGoogle Scholar
• 10 Svensson P J, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis.  N Engl J Med . 1994;  330 517-522
  CrossrefPubMedGoogle Scholar
• 11 Bertina R M, Koeleman B PC, Koster T. et al . Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature . 1994;  369 64-67
  CrossrefPubMedGoogle Scholar
• 12 De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications.  Semin Thromb Hemost . 1998;  24 367-379
  PubMedGoogle Scholar
• 13 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood . 1996;  88 3698-3703
  CrossrefPubMedGoogle Scholar
• 14 Rosendaal F R, Doggen C JM, Zivelin A. et al . Geographic distribution of the 20210 G to A prothrombin variant.  Thromb Haemost . 1998;  79 706-708
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Rosendaal F R. Venous thrombosis: a multicausal disease.  Lancet . 1999;  353 1167-1173
  CrossrefPubMedGoogle Scholar
• 16 Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population.  J Intern Med . 1992;  232 155-160
  PubMedGoogle Scholar
• 17 Anderson F A, Wheeler H B, Goldberg R J. et al . A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study.  Arch Intern Med . 1991;  151 933-938
  CrossrefPubMedGoogle Scholar
• 18 Andersen B S, Steffensen F H, Sorensen H T, Nielsen G L, Olsen J. The cumulative incidence of venous thromboembolism during pregnancy and puerperium. An 11 year Danish population-based study of 63,300 pregnancies.  Acta Obstet Gynecol Scand . 1998;  77 170-173
  CrossrefPubMedGoogle Scholar
• 19 Mc Coll D M, Ramsay J E, Tait R C. et al . Risk factors for pregnancy associated venous thromboembolism.  Thromb Haemost . 1997;  78 1183-1188
  PubMedGoogle Scholar
• 20 Rosendaal F R. Risk factors for venous thrombotic disease.  Thromb Haemost . 1999;  82 610-619
  PubMedGoogle Scholar
• 21 Ray J C, Chan W S. Deep vein thrombosis during pregnancy and puerperium: a meta-analysis of the period of risk and the leg of presentation.  Obstet Gynecol Surv . 1999;  54 265-271
  CrossrefPubMedGoogle Scholar
• 22 Grandone E, Margaglione M, Colaizzo D. et al . Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations.  Am J Obstet Gynecol . 1998;  179 1324-1328
  CrossrefPubMedGoogle Scholar
• 23 Martinelli I, De Stefano V, Taioli E. et al . Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium.  Thromb Haemost . 2002;  87 791-795
  PubMedGoogle Scholar
• 24 Gerhardt A, Scharf R E, Beckmann M W. et al . Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.  N Engl J Med . 2000;  342 374-380
  CrossrefPubMedGoogle Scholar
• 25 Conard J, Horellou M H, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women.  Thromb Haemost . 1990;  63 319-320
  PubMedGoogle Scholar
• 26 De Stefano V, Leone G, Mastrangelo S, Tripodi A. et al . Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S.  Thromb Haemost . 1994;  71 799-800
  PubMedGoogle Scholar
• 27 Vicente V, Rodriguez C, Soto I, Fernandez M, Moraleda J M. Risk of thrombosis during pregnancy and post-partum in hereditary thrombophilia.  Am J Hematol . 1994;  46 151-152
  PubMedGoogle Scholar
• 28 Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study.  Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol . 1996;  16 742-748
  CrossrefPubMedGoogle Scholar
• 29 Friederich P W, Sanson B J, Simioni P. et al . Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis.  Ann Intern Med . 1996;  125 955-960
  CrossrefPubMedGoogle Scholar
• 30 Dizon-Townson D S, Nelson L M, Jang H, Varner M W, Ward K. The incidence of factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis.  Am J Obstet Gynecol . 1997;  176 883-886
  PubMedGoogle Scholar
• 31 Lindqvist P G, Svensson P J, Marsaal K. et al . Activated protein C resistance (FV:Q506) and pregnancy.  Thromb Haemost . 1999;  81 532-537
  PubMedGoogle Scholar
• 32 Murphy R P, Donoghue C, Nallen R J. et al . Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy.  Arterioscler Thromb Vasc Biol . 2000;  20 266-270
  PubMedGoogle Scholar
• 33 De Stefano V, Mastrangelo S, Paciaroni K. et al . Thrombotic risk during pregnancy and puerperium in women with APC-resistance. Effective subcutaneous heparin prophylaxis in a pregnant patient.  Thromb Haemost . 1995;  74 793-794
  PubMedGoogle Scholar
• 34 Bokarewa M I, Bremme K, Blomback M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy.  Br J Haematol . 1996;  92 473-478
  CrossrefPubMedGoogle Scholar
• 35 Hirsch D R, Mikkola K M, Marks P W. et al . Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden.  Am Heart J . 1996;  131 1145-1148
  CrossrefPubMedGoogle Scholar
• 36 Hallak M, Senderowicz J, Cassel A. et al . Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.  Am J Obstet Gynecol . 1997;  176 889-893
  PubMedGoogle Scholar
• 37 McColl M D, Ellison J, Reid F. et al . Prothrombin 20210 G→A, MTHF C677T mutations in women with venous thromboembolism associated with pregnancy.  Br J Obstet Gynaecol . 2000;  107 565-569
  PubMedGoogle Scholar
• 38 Martinelli I, Legnani C, Bucciarelli P. et al . Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia.  Thromb Haemost . 2001;  86 800-803
  PubMedGoogle Scholar
• 39 Middeldorp S, Libourel E, Hamulyàk K, van der Meer J, Buller H. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden.  Br J Haematol . 2001;  113 553-555
  CrossrefPubMedGoogle Scholar
• 40 Brill-Edwards P, Ginsberg J S, Gent M. et al . Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clots in This Pregnancy Study Group.  N Engl J Med . 2000;  343 1439-1444
  CrossrefPubMedGoogle Scholar
• 41 Abildgaard U, Viskjold F, Majak P. Hereditary antithrombin deficiency and pregnancy: venous thromboembolism despite prophylaxis with LMW heparin (Abst).  Thromb Haemost . 2001;  Suppl P1470
  PubMedGoogle Scholar
• 42 Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin.  Gynecol Obstet Invest . 1982;  14 127-141
  PubMedGoogle Scholar
• 43 De Stefano V, Leone G, De Carolis S. et al . Management of pregnancy in women with antithrombin III congenital defect: report of four cases.  Thromb Haemost . 1988;  59 193-196
  PubMedGoogle Scholar
• 44 Kupferminc M J, Eldor A, Steinman N. et al . Increased frequency of genetic thrombophilia in women with complications of pregnancy.  N Engl J Med . 1999;  340 9-13
  CrossrefPubMedGoogle Scholar
• 45 Dovey D A, MacGillivray I. The classification and definition of hypertensive disorders of pregnancy.  Am J Obstet Gynecol . 1988;  158 892-898
  CrossrefPubMedGoogle Scholar
• 46 Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy.  Am J Obstet Gynecol . 1982;  142 159-167
  PubMedGoogle Scholar
• 47 Saftlas A F, Olson D R, Franks A L, Atrash H K, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986.  Am J Obstet Gynecol . 1990;  163 460-465
  PubMedGoogle Scholar
• 48 Kupferminc M J, Fait G, Many A. et al . Severe preeclampsia and high frequency of genetic thrombophilic mutations.  Obstet Gynecol . 2000;  96 45-49
  CrossrefPubMedGoogle Scholar
• 49 De Groot J M C, Bloemenkamp K WM, Duvekot E J. et al . Preeclampsia and genetic risk factors for thrombosis: a case-control study.  Am J Obstet Gynecol . 1999;  181 975-980
  CrossrefPubMedGoogle Scholar
• 50 Dizon-Towson D S, Nelson L M, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia.  Am J Obstet Gynecol . 1996;  175 902-905
  CrossrefPubMedGoogle Scholar
• 51 Grandone E, Margaglione M, Colaizzo D. et al . Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia.  Thromb Haemost . 1997;  77 1052-1054
  PubMedGoogle Scholar
• 52 Krauss T, Augustin H G, Osmers R. et al . Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome.  Obstet Gynecol . 1998;  92 457-460
  CrossrefPubMedGoogle Scholar
• 53 Nagy B, Toth T, Rigo Jr J. et al . Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women.  Clin Genet . 1998;  53 478-481
  CrossrefPubMedGoogle Scholar
• 54 van Pampus G M, Dekker G A, Wolf H. et al . High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia.  Am J Obstet Gynecol . 1999;  180 1146-1150
  CrossrefPubMedGoogle Scholar
• 55 Grandone E, Margaglione M, Colaizzo D. et al . Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria.  Thromb Hemost . 1999;  81 349-352
  PubMedGoogle Scholar
• 56 O'Shaughnessy K M, Fu B, Ferraro F. et al . Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an East Anglian preeclampsia cohort.  Hypertension . 1999;  33 1338-1341
  PubMedGoogle Scholar
• 57 Livingston J C, Barton J R, Park V. et al . Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia.  Am J Obstet Gynecol . 2001;  185 153-157
  CrossrefPubMedGoogle Scholar
• 58 Ventura S J, Taffel S M, Mosher W D. Estimates of pregnancies and pregnancy rates for the United States, 1976-85.  Am J Public Health . 1988;  78 506-511
  CrossrefPubMedGoogle Scholar
• 59 Stirrat G M. Recurrent miscarriage. I. Definition and epidemiology.  Lancet . 1990;  336 673-675
  CrossrefPubMedGoogle Scholar
• 60 Samueloff A, Xenakis E M, Berkus M D, Huff R W, Langer O. Recurrent stillbirth: significance and characteristics.  J Reprod Med . 1993;  38 883-886
  PubMedGoogle Scholar
• 61 Gris J C, Quere I, Monpeyroux F. et al . Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent. The Nimes Obstetricians and Haematologists Study(NOHA).  Thromb Haemos . 1999;  81 891-899
  PubMedGoogle Scholar
• 62 Brenner B. Inherited thrombophilia and pregnancy loss.  Thromb Haemost . 1999;  82 634-640
  PubMedGoogle Scholar
• 63 Preston F E, Rosendaal F R, Walker I D. et al . Increased fetal loss in women with heritable thrombophilia.  Lancet . 1996;  348 913-916
  CrossrefPubMedGoogle Scholar
• 64 Sanson B J, Friederich P W, Simioni P. et al . The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women.  Thromb Haemost . 1996;  75 387-388
  PubMedGoogle Scholar
• 65 Gris J C, Ripart-Neveu S, Maugard C. et al . Retrospective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study.  Thromb Haemost . 1997;  77 1096-1103
  PubMedGoogle Scholar
• 66 Meinardi J R, Middeldorp S, de Kam J P. et al . Increased risk for fetal loss in carriers of the factor V Leiden mutation.  Ann Intern Med . 1999;  130 736-739
  PubMedGoogle Scholar
• 67 Tormene D, Simioni P, Prandoni P. et al . The risk of fetal loss in family members of probands with factor V Leiden mutation.  Thromb Haemost . 1999;  82 1237-1239
  PubMedGoogle Scholar
• 68 Grandone E, Margaglione M, Colaizzo D. et al . Factor V Leiden is associated with repeated and recurrent unexplained fetal losses.  Thromb Haemost . 1997;  77 822-824
  PubMedGoogle Scholar
• 69 Ridker P M, Miletich J P, Buring J E. et al . Factor V Leiden mutation as a risk factor for recurrent pregnancy loss.  Ann Intern Med . 1998;  128 1000-1003
  PubMedGoogle Scholar
• 70 Brenner B, Sarig G, Weiner Z. et al . Thrombophilic polymorphisms are common in women with fetal loss without apparent cause.  Thromb Haemost . 1999;  82 6-9
  PubMedGoogle Scholar
• 71 Souza S S, Ferriani R A, Pontes A G, Zago M A, Franco R F. Factor V Leiden and factor II G20210A mutations in patients with recurrent abortion.  Hum Reprod . 1999;  14 2448-2450
  CrossrefPubMedGoogle Scholar
• 72 Foka Z J, Lambropoulos A F, Saravelos H. et al . Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages.  Hum Reprod . 2000;  15 458-462
  CrossrefPubMedGoogle Scholar
• 73 Younis J S, Brenner B, Ohel G. et al . Activated protein C resistance and factor V Leiden mutation can be associated with first- as well as second-trimester recurrent pregnancy loss.  Am J Reprod Immunol . 2000;  43 31-35
  CrossrefPubMedGoogle Scholar
• 74 Martinelli I, Taioli E, Cetin I. et al . Mutations in coagulation factors in women with unexplained late fetal loss.  N Engl J Med . 2000;  343 1015-1018
  CrossrefPubMedGoogle Scholar
• 75 Wramsby M L, Sten-Linder M, Bremme K. Primary habitual abortions are associated with high frequency of factor V Leiden mutation.  Fertil Steril . 2000;  74 987-991
  CrossrefPubMedGoogle Scholar
• 76 Kupferminc M J, Peri H, Zwang E. et al . High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss.  Acta Obstet Gynecol Scand . 2000;  79 963-967
  CrossrefPubMedGoogle Scholar
• 77 Martinelli P, Grandone E, Colaizzo D. et al . Familial thrombophilia and the occurrence of fetal growth restriction.  Haematologica . 2001;  86 428-431
  PubMedGoogle Scholar
• 78 Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae.  Am J Obstet Gynecol . 1998;  179 1565-1567
  CrossrefPubMedGoogle Scholar
• 79 Younis J S, Ohel G, Brenner B. et al . The effect of thromboprophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation.  BJOG . 2000;  107 415-419
  PubMedGoogle Scholar
• 80 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J S. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.  Thromb Haemost . 2000;  83 693-697
  PubMedGoogle Scholar
• 81 Vandenbroucke J P, Rosing J, Bloemenkamp K WM. et al . Medical progress: oral contraceptives and the risk of venous thrombosis.  N Engl J Med . 2001;  344 1527-1535
  CrossrefPubMedGoogle Scholar
• 82 Kemmeren J K, Algra A, Grobbee D E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.  BMJ . 2001;  323 1-9
  CrossrefPubMedGoogle Scholar
• 83 Bloemenkamp K W, Rosendaal F R, Helmerhorst F M, Vandenbroucke J P. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting factors.  Arch Intern Med . 2000;  160 49-52
  CrossrefPubMedGoogle Scholar
• 84 Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors.  Thromb Haemost . 1994;  71 548-552
  PubMedGoogle Scholar
• 85 Vandenbroucke J P, Koster T, Briet E. et al . Increased risk of venous thrombosis in oral contraceptives users who are carriers of factor V Leiden mutation.  Lancet . 1994;  344 1453-1457
  CrossrefPubMedGoogle Scholar
• 86 Bloemenkamp K W, Rosendaal F R, Helmerhorst F M, Buller H R, Vandenbroucke J P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.  Lancet . 1995;  346 1593-1596
  CrossrefPubMedGoogle Scholar
• 87 Andersen B S, Olsen J, Nielsen G L. et al . Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism.  Thromb Haemost . 1998;  79 28-31
  PubMedGoogle Scholar
• 88 Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci P M. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis.  Arterioscler Thromb Vasc Biol . 1999;  19 700-703
  CrossrefPubMedGoogle Scholar
• 89 Spannagl M, Heinemann L A, Schramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?.  Eur J Contracept Reprod Health Care . 2000;  5 105-112
  CrossrefPubMedGoogle Scholar
• 90 Emmerich J, Rosendaal F R, Cattaneo M. et al . Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism. Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.  Thromb Haemost . 2001;  86 809-816
  Article in Thieme ConnectPubMedGoogle Scholar
• 91 Santamaria A, Mateo J, Oliver A. et al . Risk of thrombosis associated with oral contraceptives in women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene.  Haematologica . 2001;  86 965-971
  PubMedGoogle Scholar
• 92 Rintelen C, Mannhalter C, Ireland H. et al . Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.  Br J Haematol . 1996;  93 487-490
  CrossrefPubMedGoogle Scholar
• 93 Rosing J, Tans G, Nicolaes G A. et al . Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.  Br J Haematol . 1997;  97 233-238
  CrossrefPubMedGoogle Scholar
• 94 Martinelli I, Sacchi E, Landi G. et al . High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.  N Engl J Med . 1998;  338 1793-1797
  CrossrefPubMedGoogle Scholar
• 95 Rosendaal F R, Helmerhorst F M, Vandenbroucke J P. Oral contraceptives, hormone replacement therapy and thrombosis.  Thromb Haemost . 2001;  86 112-123
  PubMedGoogle Scholar
• 96 Hoibraaten E, Qvigstad E, Arnesen H. et al . Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Results of the randomized, double-blind, placebo controlled estrogen in venous thromboembolism trial (EVTET).  Thromb Haemost . 2000;  84 961-967
  PubMedGoogle Scholar